TY - JOUR
T1 - Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis
AU - Wiese, Michael
AU - Rowland, Andrew
AU - Polasek, Thomas
AU - Sorich, Michael
AU - O'Doherty, Catherine
PY - 2013/8
Y1 - 2013/8
N2 - Introduction: Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012. Its primary mode of action is inhibition of dihydroorotate dehydrogenase which inhibits the proliferation of activated T cells, but it also has a number of other actions that may be important contributors to its efficacy in MS. Areas covered: This review covers a basic pathophysiology of MS and the current treatment options, including a discussion of the needs for additional treatments. The main focus of the review is the pharmacokinetics and pharmacodynamics of teriflunomide, including a brief comparison with the disease-modifying antirheumatic drug leflunomide. The authors discuss the clinical efficacy and toxicity profile of teriflunomide and make some comparisons with treatments that are currently, or soon to be available. Expert opinion: While teriflunomide is no more effective than a number of other agents that are used in the treatment of MS, it has a favorable side-effect profile and the convenience of once a day oral administration. As such, it is likely to be a popular agent in the treatment of MS over the next 5 years.
AB - Introduction: Teriflunomide is an immunomodulatory drug that received FDA approval for the treatment of relapsing forms of multiple sclerosis (MS) in September 2012. Its primary mode of action is inhibition of dihydroorotate dehydrogenase which inhibits the proliferation of activated T cells, but it also has a number of other actions that may be important contributors to its efficacy in MS. Areas covered: This review covers a basic pathophysiology of MS and the current treatment options, including a discussion of the needs for additional treatments. The main focus of the review is the pharmacokinetics and pharmacodynamics of teriflunomide, including a brief comparison with the disease-modifying antirheumatic drug leflunomide. The authors discuss the clinical efficacy and toxicity profile of teriflunomide and make some comparisons with treatments that are currently, or soon to be available. Expert opinion: While teriflunomide is no more effective than a number of other agents that are used in the treatment of MS, it has a favorable side-effect profile and the convenience of once a day oral administration. As such, it is likely to be a popular agent in the treatment of MS over the next 5 years.
KW - ABCG2
KW - Dihydroorotate dehydrogenase
KW - Leflunomide
KW - Multiple sclerosis
KW - Pharmacokinetics
KW - Teriflunomide
KW - TFMA oxalinate
UR - http://www.scopus.com/inward/record.url?scp=84880374675&partnerID=8YFLogxK
U2 - 10.1517/17425255.2013.800483
DO - 10.1517/17425255.2013.800483
M3 - Article
VL - 9
SP - 1025
EP - 1035
JO - Expert Opinion on Drug Metabolism and Toxicology
JF - Expert Opinion on Drug Metabolism and Toxicology
SN - 1742-5255
IS - 8
ER -